Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 6/20 | 0.35 |
| ▸ | JAK2 | O60674 | 4/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 3/20 | 0.32 |
| ▸ | BTD | P43251 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17546299 | 0.90 | POLB (0.44) | POLBPDE4BDPP4VNN1BTD | |
| SCHEMBL19014557 | 0.89 | POLB (0.56) | POLBPDE4BLRRK2DPP4 | |
| SCHEMBL17546303 | 0.85 | POLB (0.48) | POLBJAK1JAK2JAK3 | |
| SCHEMBL6826789 | 0.84 | POLB (0.48) | POLBPDE4B | |
| SCHEMBL20647896 | 0.81 | DPP4 (0.45) | PDE4BJAK1JAK2JAK3TYK2 | |
| SCHEMBL19249276 | 0.81 | DPP4 (0.45) | PDE4BJAK1JAK2JAK3TYK2 | |
| SCHEMBL16887553 | 0.79 | DPP4 (0.38) | JAK1JAK2JAK3DPP4 | |
| SCHEMBL27510701 | 0.79 | F2R (0.36) | JAK1JAK2JAK3LRRK2TYK2 | |
| SCHEMBL28244560 | 0.79 | CHRNB2 (0.41) | PDE4BLRRK2DPP4 | |
| SCHEMBL18389813 | 0.78 | KDM4E (0.46) | POLBUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | POLB 4110/4885PDE4B 368/4885JAK1 364/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | POLB 4110/4885PDE4B 368/4885JAK1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.